CTXR

👉  CTXR is TODAY’S #1 ALERT 👈

Top of the morning to you, folks!

The S&P 500 hit a new all-time high yesterday, and futures are looking essentially flat as the markets await the release of last month’s FOMC minutes at 2:00 EST.

I hope you managed to catch the awesome “tactical trade” idea I alerted before the bell yesterday…

I’m on a big streak of double-digit gainers on these ideas (now 12 of the last 13 have hit that mark), but I really outdid myself yesterday as you saw.

This one was a triple-digit mover! 💯

At its peak, it hit a 115% gain on the day.  Keep in mind that was all in just a few hours after I sent you the morning alert.

But that wasn’t a mere spike. Most of the trading day, the stock was up 70% or better, which is where it closed.

And again, I identified that bad boy before the market opened. I wasn’t just riding the bandwagon. 

Which brings me to today’s “tactical trade” idea…

Go ahead and pull up Citius Pharmaceuticals Inc (CTXR) right now.

The first thing you’ll notice is that the stock is absolutely ripping in pre-market trading this morning…

After a slight pullback in yesterday’s trading, CTXR is already roaring back with a vengeance this morning – up double-digits already.

Volume is going nuts already, as well.

CTXR is certainly on the radar of a lot of traders this morning as a top rebound play.  

This could be a very big day for CTXR – Make sure it is on the top of your watchlist!

To help get you started with your due diligence today, here are some highlights on the company I think you should strongly consider:

     1.FDA Green Light for LYMPHIR™ 🟢

Citius scored a significant win with the FDA approval of LYMPHIR™, their treatment for relapsed cutaneous T-cell lymphoma. This marks their first approved therapy, setting the stage for its launch in the first half of 2025. Notably, LYMPHIR™ has been assigned a permanent J-code (J9161), effective April 1, 2025, streamlining insurance reimbursements.

     2.Strategic Spin-Off: Citius Oncology 🚀

In August 2024, Citius restructured by merging its oncology subsidiary with TenX Keane Acquisition, forming Citius Oncology, Inc. This move not only sharpened their focus on oncology but also provided a unique investment avenue, with Citius Pharmaceuticals retaining approximately 90% ownership.

     3.Mino-Lok®: A Potential Game-Changer 💉

Beyond LYMPHIR™, Citius is advancing Mino-Lok®, an antibiotic lock solution aimed at salvaging infected central venous catheters. With a global market potential estimated at $1.8 billion, this therapy could revolutionize infection control in critical care settings.

     4. Expanding Pipeline with High-Impact Therapies 🔬

Citius isn’t just a one-hit wonder. Besides LYMPHIR™ and Mino-Lok®, they’ve got a strong pipeline of innovative treatments, including Halo-Lido, a late-stage therapy for hemorrhoid relief, and Mino-Wrap, a bio-absorbable antimicrobial wrap designed to reduce infections in breast reconstruction surgeries. 🚀 These aren’t just niche plays—each one targets a significant market with high unmet needs.

📌 Why it matters: Citius is building a diversified portfolio, increasing its chances of delivering multiple successful therapies and reducing risk by not relying on a single drug.

     5. Leadership with Skin in the Game 🧠

The company’s leadership isn’t just at the helm; they’re heavily invested, with founders contributing $26.5 million. This significant insider investment reflects a strong commitment to the company’s success and aligns their interests with those of other shareholders.

In essence, Citius Pharmaceuticals is navigating a transformative phase, balancing groundbreaking therapeutic developments with financial challenges. Their strategic initiatives and leadership’s vested interest position them uniquely in the biotech landscape.

The New Jersey-based company is set to completely transform the standard of care in patients with infections stemming from Central Venous Catheters (CVCs).

If its lead candidate, Mino-Lok, is approved — and that’s looking increasingly likely — it would be the first and only FDA-approved antibiotic lock solution for salvaging CVCs.

That may not sound like the most exciting thing, but it would actually be a really huge deal.

For those who don’t know, CVCs are thin tubes that are inserted into large veins in the chest, neck, or groin.

They’re used to provide patients with medications, fluids, and nutrition and for regular blood sampling.

Every year, 7 million CVCs are used in the U.S., and 4 million of those are long-term, meaning they get used longer than a month.

Each year, approximately 500,000 of these catheters become infected, resulting in conditions known as central line-associated bloodstream infection (CLABSI) and catheter-related bloodstream infection (CRBSI).

The standard “cure” for CLABSI/CRBSI is for the patient to take a round of antibiotics and have the CVC removed and replaced.

The problem is it is extremely painful and traumatizing to remove/replace a CVC, and it can interrupt care for the patient’s underlying condition…

(Many of these patients are extremely vulnerable — undergoing chemotherapy, ICU patients, etc.)

One study found that 57%–67% of patients had adverse physical and psychological symptoms from CVC removal and replacement, with 32% experiencing moderate-to-severe symptoms.

It’s also very expensive, costing approximately $10,000 and the overall CLABSI/CRBSI treatment can cost as much as $65,000.

CTXR is hoping to replace this lackluster standard of care with Mino-Lok, an antibiotic solution intended to actually salvage infected catheters.

Mino-Lok has gone through a complete Phase 3 trial and the company reported topline results on May 21, noting that it had achieved the primary endpoint and several secondary endpoints with very high statistical significance.

Citius CEO Leonard Mazur said the CTXR is “extremely pleased by the strong results,” and that the company is preparing the full data analysis, then will meet with the FDA to discuss the path to NDA submission and commercialization.

The company estimates the potential market for Mino-Lok at more than $1 billion in the U.S. and $2 billion globally.

Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: CTXR has a strong pipeline that included its recent, first-ever FDA approval. MINO-Lok and Halo-Lido could also transform the standards of care for their indications.

With the powerful price action we’re already seeing in pre-market trading, I think we could see a very big day ahead of us.

Pay close attention to CTXR today, and see if the momentum continues.

To Your Success,

Jeff Bishop

P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now. 

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on February 19, 2025.  Before this, we received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on September 23, 2024, and we also received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on July 11, 2024 as well as fifteen thousand dollars via ach bank transfer by Lifewater Media for advertising Citius Pharmaceuticals for a one marketing program on March 9th, 2023. These amounts were paid by someone else not connected to Citius Pharmaceuticals. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Citius Pharmaceuticals might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.